CBP-501

CBP-501 is a chemically modified duodecapeptide and analog of M-phase inducer phosphatase 3 (CDC25C), developed as an anti-cancer agent. It acts primarily as a G2 checkpoint inhibitor, targeting multiple serine/threonine kinases including MAPKAP-K2, C-Tak1, and CHK1, which are involved in the phosphorylation of CDC25C. By disrupting CDC25C activity, CBP-501 abrogates DNA repair at the G2 checkpoint and enhances cell cycle arrest. Additionally, it binds to calmodulin, increasing cisplatin influx into tumor cells and enhancing platinum-DNA adduct formation—thereby sensitizing cancer cells to platinum-based chemotherapy such as cisplatin or bleomycin. The drug has shown particular efficacy in combination with cisplatin against mesothelioma cell lines but did not improve standard chemotherapy outcomes for malignant pleural mesothelioma in clinical studies. CBP-501 also induces immunogenic tumor cell death when used with platinum agents[1][3][4][5][6][8].

Other names

Cdc25C phosphatase 211-221Cdc-25C phosphatase 211-221Cdc 25C phosphatase 211-221